Background {#Sec1}
==========

Viral hepatitis is now one of the major causes of death through communicable disease \[[@CR1]\]. WHO estimates that 240 million people currently have chronic hepatitis B virus (HBV) infection \[[@CR2]\]. HBV infection accounts more than 1 million deaths worldwide from cirrhosis, liver failure, and hepatocellular carcinoma \[[@CR3]\]. Despite advances in treatment, eradication of the hepatitis B virus from patients with chronic hepatitis B is rarely achieved \[[@CR4]\]. Prevention through vaccination is vital to control HBV infection.

Data from the GeoSentinel Surveillance Network shows that the most common vaccine preventable diseases among travelers returning home ill were enteric fever, acute viral hepatitis and influenza. Hepatitis B infection was the fourth most common after enteric fever, acute hepatitis A and influenza \[[@CR5]\]. A study of Australian and European travelers found that approximately 30--65 % of travelers to HBV endemic countries undertook activities that potentially exposed them to HBV \[[@CR6], [@CR7]\]. Furthermore, less than half of the travelers (46 %) had been vaccinated against HBV \[[@CR6]\]. The HBV vaccination rate of people travelling abroad is different in each region \[[@CR8]\]. There are many reasons why people did not opt for pre-travel vaccinations, these include the traveler's lack of awareness regarding the prevention of diseases during overseas travel, the limited number of healthcare vaccination facilities and that some countries have yet to approve a number of vaccines needed by travelers \[[@CR9]\]. This review aims to explore the need for HBV vaccination among international travelers to Asia.

International travelers to Asia {#Sec2}
-------------------------------

Asia is one of the major global tourist destinations, with more than 263 million international tourist arrivals in 2014 \[[@CR10]\]. Six of the top ten most visited cities were located in Asia \[[@CR11]\]. China received more than 55 million visits in 2014, making it the most visited country in Asia that year \[[@CR10]\]. Most tourist countries in Asia have intermediate to high HBV prevalence. Most of these countries have implemented universal HBV vaccination. However, vaccine coverage and completeness, measured by delivery of all three doses, of HBV vaccination are still limited in some countries \[[@CR12]\]. Furthermore, the majority of those receiving immunization tend to be the young population who were born after the initiation of WHO's Expanded Program on Immunization (EPI) (Table [1](#Tab1){ref-type="table"}).Table 1Prevalence of chronic hepatitis B and coverage of expanded program on HBV immunization in Asian countries receiving a high number of travelers \[[@CR10], [@CR12], [@CR14]\]Arrival CountryInternational traveler's arrivals per year (2014)Estimated prevalence of chronic hepatitis B infection^a^Estimated HBsAg positive populationImplement of Expanded program of immunization (EPI) for HBV (Year)Complete HBV vaccination at year 2014 (%)Population age after EPI deployed at year 2016China55,622,0005.49 %74,601,20420009916Malaysia27,437,0000.74 %208,54019899627Thailand24,780,0006.42 %4,260,00819929924Saudi Arabia15,098,0003.18 %866,67519909826South Korea14,202,0004.36 %2,111,91419959921Japan13,413,0001.02 %1,294,431NoNo0Singapore11,858,0004.09 %207,94319909726Indonesia9,435,0001.86 %4,468,68419927824India7,703,0001.46 %17,553,38920047012Vietnam7,874,00010.79 %9,607,43820039513Philippines4,833,0004.63 %4,326,21219957921Cambodia4,503,0004.05 %581,59620069710Jordan3,990,0001.86 %119,91919959818Myanmar3,081,0003.40 %1,765,64320037513Laos2,510,0008.74 %558,71020038813Estimated at year 2015 based on data on prevalence of chronic HBV infection published between Jan 1, 1965, and Oct 23, 2013^a^

A large proportion of international travelers to Asia depart from Europe and North America \[[@CR13]\]. Most countries in those regions are classified as low HBV prevalence \[[@CR14]\]. Therefore many countries do not have universal HBV vaccination \[[@CR12]\]. Overall prevalence of hepatitis B infection and coverage of the Expanded Program on HBV Immunization in selected countries with high international traveler's departures to Asia is summarized in Table [2](#Tab2){ref-type="table"}.Table 2Prevalence of CHB and coverage of expanded program on HBV immunization in international traveler's to Asia departure countries outside Asia \[[@CR12]--[@CR14]\]RegionCountryInternational traveler's departures per year (2013)Estimated prevalence of chronic hepatitis B infection^a^Estimated HBsAg positive populationStart of Expanded Program of Immunization (EPI) for HBV (Year)Complete HBV vaccination (%)Number of years since EPI deployed, at year 2016N. AmericaUSA61,569,0000.27 %843,72419939023Canada32,977,0000.76 %260,86520037513S. AmericaMexico15,911,0000.20 %237,85820008416Argentina7,544,0000.77 %312,80620029414EuropeUnited Kingdom58,510,0000.01 %3,300Not startedN/AN/ARussia54,069,0002.73 %3,926,49920019715Italy27,798,0002.52 %1,522,54619919425France26,243,0000.26 %165,72819988218Ukraine23,761,0001.45 %666,28020004616Netherlands18,094,0000.40 %67,0092013952Hungary15,997,0000.53 %53,301Not startedN/AN/ASweden15,917,0000.59 %55,6062011425Spain11,246,0000.34 %158,28719969620OceaniaAustralia8,768,0000.37 %83,12120019115New Zealand2,193,0004.11 %179,35719929324AfricaSouth Africa5,168,0006.70 %3,445,47719977419Uganda378,0009.19 %3,123,88620027814^a^ Estimated at year 2015 based on data on prevalence of chronic HBV infection published between Jan 1, 1965, and Oct 23, 2013

Risk of HBV infection during travel {#Sec3}
-----------------------------------

HBV transmission routes in travelers are through percutaneous or mucosal exposure of HBV‐infected blood or bodily fluids including saliva or semen; via sexual contact, contaminated blood products, contaminated medical equipment, and via sharing needles and injecting apparatus \[[@CR15]\]. In people using needles contaminated with HBV, the risk of developing infection is approximately 30 % \[[@CR16]\]. These routes are different from the usual routes of transmission in high prevalence areas where vertical transmission, when an infected mother transmits the infection to her offspring, is most common \[[@CR17]\].

Travelers such as expatriates, those visiting friends and relatives, and travelers engaging in casual sex, dental surgery, and medical procedures may be at greater risk of HBV infection \[[@CR6]\]. Younger travelers and those travelers with a longer duration of travel are also at greater risk of HBV infection \[[@CR18], [@CR19]\]. A study of international backpackers in Thailand, found that 25 % of those travelers had had casual sex while travelling and almost half did not always use condom \[[@CR20]\]. A study of Dutch travelers to tropical and sub-tropical destinations found that the risk of infection from unprotected sex increased with the number of partners and the incidence of unprotected sex was higher among single travelers \[[@CR21]\]. A study by Leggat PA, et al., showed that about half of Australian travelers had participated in at least one activity with a HBV risk during their last overseas trip to Southeast or East Asia \[[@CR22]\]. Non-immune travelers traveling to high HBV prevalence countries might be at risk of HBV infection due to the many potential accidental and uncontrollable exposures during travel.

Prevalence of HBV infection in Asia {#Sec4}
-----------------------------------

HBsAg seroprevalence is estimated to be around 3.61 % worldwide. The seroprevalence varies in different regions, with the lowest rates in North America and the highest in Africa. Overall prevalence of HBV infection in Asia is estimated to be 5.26 %, with rates varying between countries \[[@CR14]\]. Estimated prevalence of chronic hepatitis B infection in Asian countries receiving a high number of travelers is summarized in Table [1](#Tab1){ref-type="table"}. HBV infection is highly endemic in Southeast Asia and China with a rate of chronic infection of 7--10 % among the general population in these areas \[[@CR23], [@CR24]\]. Prevalence of HBV infections are classified as low (\<2 %), low intermediate (2--4.99 %), high intermediate (5--7.99 %) and high (≥8 %). Estimates based on published data of prevalence of HBV infections from 1965 to 2013 show many countries in Asia to be intermediate to high endemic (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR14]\]. Based on recent data, Mongolia, Laos, Vietnam and Papua New Guinea are classified with having high prevalence of chronic hepatitis B infection \[[@CR14]\].Fig. 1Estimated prevalence of chronic hepatitis B infection in Asia at 2015

A study by Posuwan N, et al. showed that the prevalence on HBsAg positive subjects in Thailand decreased from 5--6 % to less than 1 % by 2014, after the implementation of EPI in 1992 \[[@CR17]\]. Studies from Luo Z et al., Mohammadi Z, et al. and Kim H, et al. have also shown the impact of EPI through documenting the decreasing prevalence of HBV infection in China, Iran and Korea \[[@CR23], [@CR25], [@CR26]\].

Universal HBV vaccination was recommended by World Health Organization (WHO) in 1997 \[[@CR27]\]. In the 20 years that followed, almost all countries in Asia incorporated HBV vaccination into their national infant immunization programs \[[@CR12]\]. In 2014, WHO and UNICEF estimated 62 % of countries in Asia had achieved more than 90 % coverage of completed (three doses) HBV vaccination (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR12], [@CR28]\]. The prevalence of HBV infection and the risk to travelers are likely to decrease as universal vaccination of infants is progressively implemented \[[@CR29]\].Fig. 2Estimated coverage of HBV vaccination in Asia in 1994, 2004, 2014

Universal HBV vaccination decreases HBsAg seroprevalence in young age groups and vaccine induced protection from HBV infection in the young population after implementation of universal HBV vaccination is moderately high (68.5 %) \[[@CR17], [@CR30]\].

Vaccine effectiveness and EPI has led to a strong reduction in HBsAg prevalence in Southeast Asia in the youngest age group (0--14 years) where prevalence levels were 1.2--1.4 % in 2005. In contrast, prevalence in Southeast Asian adults was still high intermediate and this age group is the most likely to interact with travelers \[[@CR31]\].

HBV Vaccination for travelers {#Sec5}
-----------------------------

Current commercially available hepatitis B vaccines are the recombinant Hepatitis B vaccine (Engerix-B®, GlaxoSmithKline and Recombivax HB®, Merck & Co., Inc.) and the combined hepatitis A and B vaccine (Twinrix®, GlaxoSmithKline). The complete hepatitis B vaccination needs 3 doses of vaccine. The usual schedule of the three intramuscular injections is to have the second and third administered 1 and 6 months after the first. An accelerated schedule (doses on days 0, 7, 21, and then a post-travel dose at 12 months) may be used if there is insufficient time for pre‐travel vaccination \[[@CR32]\].

HBV prevalence varies between countries, and therefore the number of people acquiring protective immunity from a previous HBV infection also varies. Recommendation of HBV vaccination should be based on likelihood of infection during travel and evidence of previous immunization from either vaccination or recovery from previous infection. In those travelers without evidence of previous HBV immunity, HBV vaccination is recommended in those with HBV exposure risks and travelling to HBV endemic country.

The US Center of Disease Control and Prevention (CDC) recommends HBV vaccination to all unvaccinated people traveling to areas with intermediate to high prevalence of chronic hepatitis B and suggests it should be considered for all international travelers, regardless of destination, depending on the traveler's potential risk exposure. High risk activities include unprotected sex with a new partner, getting a tattoo or piercing, or having any medical procedures \[[@CR33]\].

Despite the CDC recommendation, a study by Connor BA, et al. showed that only 19 % of all American travelers and 30 % of American travelers planning high risk activities had received a completed hepatitis B vaccination before departure \[[@CR18]\]. This information is consistent with data from Europe that only 15 % international travelers to HBV endemic countries receive a completed hepatitis B vaccination before travel \[[@CR34]\].

In travelers from low endemic countries and who were born before EPI, the chance of immunity to HBV is very low \[[@CR30], [@CR35]\]. Currently there are no recommendations for HBV serologic screening of international travelers. Due to the high numbers of people it is impractical to screen all international travelers and only 3.4--3.9 % of the population in low endemic countries will have serologic evidence of prior infection \[[@CR30], [@CR35]\]. Immunization of those individuals should be considered, especially if long-term travel is planned to countries with intermediate to high prevalence of HBV (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Decision Tree for Hepatitis B vaccination for international travelers to Asia

Conclusions {#Sec6}
===========

Hepatitis B is still endemic in the majority of countries in Asia. HBV infection during travel might occur in those without HBV immunity traveling in an endemic country. This article summarized the updated data that should influence a traveler's decision on whether to get the HBV vaccination before travel to Asia. Vaccination is still the best preventive measure and should be considered by those at risk of HBV infection during travel.
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